Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Bowlus

Showing results (161-170 of 189) with videos related to

Pageof 19
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 27, 2017
Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With TreatmentMei Lu, Yueren Zhou, Irina V Haller, et al.
Hepatology Communications|April 13, 2026
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studiesStuart C Gordon, Alejandra Villamil, Ira M Jacobson, et al.
The American Journal of Gastroenterology|January 28, 2020
Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary CholangitisStuart C Gordon, Kuan-Han Hank Wu, Keith Lindor, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 11, 2026
Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year AnalysisAdrielly Martins, Anish Reddy, Richard Dean, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 23, 2014
Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosisGary L Norman, Chen-Yen Yang, Heather P Ostendorff, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialGideon M Hirschfield, Christopher L Bowlus, David E J Jones, et al.
Digestive Diseases and Sciences|September 9, 2021
Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USAJia Li, Mei Lu, Yueren Zhou, et al.
JHEP Reports : Innovation in Hepatology|August 18, 2025
Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapyYu Chen, Haoyu Wen, You Li, et al.
The American Journal of Gastroenterology|June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study ResultsCynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
Pageof 19

Showing results (161-170 of 189) with videos related to

Sort By:
Pageof 19
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 27, 2017
Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With TreatmentMei Lu, Yueren Zhou, Irina V Haller, et al.
Hepatology Communications|April 13, 2026
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studiesStuart C Gordon, Alejandra Villamil, Ira M Jacobson, et al.
The American Journal of Gastroenterology|January 28, 2020
Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary CholangitisStuart C Gordon, Kuan-Han Hank Wu, Keith Lindor, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 11, 2026
Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year AnalysisAdrielly Martins, Anish Reddy, Richard Dean, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 23, 2014
Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosisGary L Norman, Chen-Yen Yang, Heather P Ostendorff, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialGideon M Hirschfield, Christopher L Bowlus, David E J Jones, et al.
Digestive Diseases and Sciences|September 9, 2021
Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USAJia Li, Mei Lu, Yueren Zhou, et al.
JHEP Reports : Innovation in Hepatology|August 18, 2025
Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapyYu Chen, Haoyu Wen, You Li, et al.
The American Journal of Gastroenterology|June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study ResultsCynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
Pageof 19